157 related articles for article (PubMed ID: 30780865)
21. Therapy for the mucopolysaccharidoses.
Valayannopoulos V; Wijburg FA
Rheumatology (Oxford); 2011 Dec; 50 Suppl 5():v49-59. PubMed ID: 22210671
[TBL] [Abstract][Full Text] [Related]
22. Residual glycosaminoglycan accumulation in mitral and aortic valves of a patient with attenuated MPS I (Scheie syndrome) after 6 years of enzyme replacement therapy: Implications for early diagnosis and therapy.
Sato Y; Fujiwara M; Kobayashi H; Yoshitake M; Hashimoto K; Oto Y; Ida H
Mol Genet Metab Rep; 2015 Dec; 5():94-97. PubMed ID: 28649551
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of recombinant human alpha-L-iduronidase (laronidase) on restricted range of motion of upper extremities in mucopolysaccharidosis type I patients.
Tylki-Szymanska A; Marucha J; Jurecka A; Syczewska M; Czartoryska B
J Inherit Metab Dis; 2010 Apr; 33(2):151-7. PubMed ID: 20217237
[TBL] [Abstract][Full Text] [Related]
24. Changes in hair morphology of mucopolysaccharidosis I patients treated with recombinant human alpha-L-iduronidase (laronidase, Aldurazyme).
Kloska A; Bohdanowicz J; Konopa G; Tylki-Szymńska A; Jakóbkiewicz-Banecka J; Czartoryska B; Liberek A; Wegrzyn A; Wegrzyn G
Am J Med Genet A; 2005 Dec; 139(3):199-203. PubMed ID: 16283671
[TBL] [Abstract][Full Text] [Related]
25. Effect of anti-laronidase antibodies on efficacy and safety of laronidase enzyme replacement therapy for MPS I: A comprehensive meta-analysis of pooled data from multiple studies.
Xue Y; Richards SM; Mahmood A; Cox GF
Mol Genet Metab; 2016 Apr; 117(4):419-26. PubMed ID: 26920513
[TBL] [Abstract][Full Text] [Related]
26. Anthropometric data of 14 patients with mucopolysaccharidosis I: retrospective analysis and efficacy of recombinant human alpha-L-iduronidase (laronidase).
Tylki-Szymanska A; Rozdzynska A; Jurecka A; Marucha J; Czartoryska B
Mol Genet Metab; 2010 Jan; 99(1):10-7. PubMed ID: 19783188
[TBL] [Abstract][Full Text] [Related]
27. [Hurler syndrome. Early diagnosis and successful enzyme replacement therapy: a new therapeutic approach. Case report].
Dupont C; El Hachem C; Harchaoui S; Ribault V; Amiour M; Guillot M; Maire I; Froissart R; Guffon-Fouilhoux N
Arch Pediatr; 2008 Jan; 15(1):45-9. PubMed ID: 18162380
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of a Combination Therapy with Laronidase and Genistein in Treating Mucopolysaccharidosis Type I in a Mouse Model.
Malinowska M; Nowicka W; Kloska A; Węgrzyn G; Jakóbkiewicz-Banecka J
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38397051
[TBL] [Abstract][Full Text] [Related]
29. [Mucopolysaccharidosis: clinical features, diagnosis and management].
Suarez-Guerrero JL; Gómez Higuera PJ; Arias Flórez JS; Contreras-García GA
Rev Chil Pediatr; 2016; 87(4):295-304. PubMed ID: 26613630
[TBL] [Abstract][Full Text] [Related]
30. Early treatment with laronidase improves clinical outcomes in patients with attenuated MPS I: a retrospective case series analysis of nine sibships.
Al-Sannaa NA; Bay L; Barbouth DS; Benhayoun Y; Goizet C; Guelbert N; Jones SA; Kyosen SO; Martins AM; Phornphutkul C; Reig C; Pleat R; Fallet S; Ivanovska Holder I
Orphanet J Rare Dis; 2015 Oct; 10():131. PubMed ID: 26446585
[TBL] [Abstract][Full Text] [Related]
31. Enzyme replacement therapy in mucopolysaccharidosis type I: progress and emerging difficulties.
Wraith JE
J Inherit Metab Dis; 2001 Apr; 24(2):245-50. PubMed ID: 11405343
[TBL] [Abstract][Full Text] [Related]
32. [Mucopolysaccharidosis I, Hurler syndrome: a case report].
Amorín M; Carlin A; Prötzel A
Arch Argent Pediatr; 2012 Oct; 110(5):e103-6. PubMed ID: 23070190
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of laronidase therapy in patients with mucopolysaccharidosis type I who initiated enzyme replacement therapy in adult age. A systematic review and meta-analysis.
Pérez-López J; Morales-Conejo M; López-Rodríguez M; Hermida-Ameijeiras Á; Moltó-Abad M
Mol Genet Metab; 2017 Jun; 121(2):138-149. PubMed ID: 28410878
[TBL] [Abstract][Full Text] [Related]
34. Laronidase-loaded liposomes reach the brain and other hard-to-treat organs after noninvasive nasal administration.
Schuh RS; Franceschi EP; Brum BB; Fachel FNS; Poletto É; Vera LNP; Santos HS; Medeiros-Neves B; Monteagudo de Barros V; Helena da Rosa Paz A; Baldo G; Matte U; Giugliani R; Ferreira Teixeira H
Int J Pharm; 2024 Jun; 660():124355. PubMed ID: 38897489
[TBL] [Abstract][Full Text] [Related]
35. Safety of laronidase delivered into the spinal canal for treatment of cervical stenosis in mucopolysaccharidosis I.
Dickson PI; Kaitila I; Harmatz P; Mlikotic A; Chen AH; Victoroff A; Passage MB; Madden J; Le SQ; Naylor DE;
Mol Genet Metab; 2015; 116(1-2):69-74. PubMed ID: 26260077
[TBL] [Abstract][Full Text] [Related]
36. Four novel mutations underlying mild or intermediate forms of alpha-L-iduronidase deficiency (MPS IS and MPS IH/S).
Tieu PT; Bach G; Matynia A; Hwang M; Neufeld EF
Hum Mutat; 1995; 6(1):55-9. PubMed ID: 7550232
[TBL] [Abstract][Full Text] [Related]
37. Growth in individuals with attenuated mucopolysaccharidosis type I during untreated and treated periods: Data from the MPS I registry.
Polgreen LE; Bay L; Clarke LA; Guffon N; Jones SA; Muenzer J; Flores AL; Wilson K; Viskochil D
Am J Med Genet A; 2022 Oct; 188(10):2941-2951. PubMed ID: 35869927
[TBL] [Abstract][Full Text] [Related]
38. A follow-up study of MPS I patients treated with laronidase enzyme replacement therapy for 6 years.
Sifuentes M; Doroshow R; Hoft R; Mason G; Walot I; Diament M; Okazaki S; Huff K; Cox GF; Swiedler SJ; Kakkis ED
Mol Genet Metab; 2007 Feb; 90(2):171-80. PubMed ID: 17011223
[TBL] [Abstract][Full Text] [Related]
39. Enzyme replacement therapy started at birth improves outcome in difficult-to-treat organs in mucopolysaccharidosis I mice.
Baldo G; Mayer FQ; Martinelli BZ; de Carvalho TG; Meyer FS; de Oliveira PG; Meurer L; Tavares A; Matte U; Giugliani R
Mol Genet Metab; 2013 May; 109(1):33-40. PubMed ID: 23562162
[TBL] [Abstract][Full Text] [Related]
40. Intrathecal enzyme replacement therapy reduces lysosomal storage in the brain and meninges of the canine model of MPS I.
Kakkis E; McEntee M; Vogler C; Le S; Levy B; Belichenko P; Mobley W; Dickson P; Hanson S; Passage M
Mol Genet Metab; 2004; 83(1-2):163-74. PubMed ID: 15464431
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
